IgG4-Related Disease: The Great Mimicker in Critical Care Medicine

A Comprehensive Review for the Intensivist

Dr Neeraj Manikath, claude.ai

Abstract

Background: IgG4-related disease (IgG4-RD) is an increasingly recognized systemic fibroinflammatory condition that can present with multiorgan involvement, often mimicking malignancy, autoimmune disorders, and infectious diseases. Its protean manifestations frequently challenge clinicians in critical care settings.

Objective: To provide a comprehensive review of IgG4-RD focusing on its multisystem presentations, diagnostic approach, and management strategies relevant to critical care physicians and postgraduate trainees.

Methods: Literature review of current evidence on IgG4-RD pathophysiology, clinical manifestations, diagnostic criteria, and therapeutic approaches.

Results: IgG4-RD presents with characteristic histopathological features including dense lymphoplasmacytic infiltration, storiform fibrosis, obliterative phlebitis, and abundant IgG4-positive plasma cells. Serum IgG4 elevation supports diagnosis but is neither sensitive nor specific. Early recognition and corticosteroid therapy can prevent irreversible organ damage.

Conclusions: IgG4-RD should be considered in the differential diagnosis of unexplained multiorgan inflammatory conditions. A systematic approach combining clinical, serological, radiological, and histopathological assessment is essential for accurate diagnosis and optimal patient outcomes.

Keywords: IgG4-related disease, autoimmune pancreatitis, retroperitoneal fibrosis, orbital pseudotumor, pulmonary nodules, storiform fibrosis

Introduction

IgG4-related disease (IgG4-RD) represents one of medicine's most fascinating diagnostic challenges—a systemic condition that can masquerade as virtually any inflammatory, infectious, or neoplastic process. First described in association with autoimmune pancreatitis in 2001, IgG4-RD has emerged as a unifying diagnosis for a constellation of previously disparate conditions affecting multiple organ systems.¹

For the critical care physician, IgG4-RD presents unique challenges. Patients may arrive in the intensive care unit with acute organ failure, mass lesions suspicious for malignancy, or multisystem inflammatory processes of unclear etiology. The condition's ability to mimic other diseases—from pancreatic adenocarcinoma to lymphoma, from infectious processes to other autoimmune conditions—makes it a true "great mimicker" that demands a high index of suspicion and systematic diagnostic approach.

Clinical Pearl: The key to recognizing IgG4-RD lies not in any single clinical feature, but in recognizing patterns: the combination of mass-forming lesions, multiorgan involvement, elevated serum IgG4, and characteristic histopathology creates a diagnostic constellation that, once recognized, becomes unmistakable.

Pathophysiology and Immunological Basis

Molecular Mechanisms

IgG4-RD represents a complex interplay of genetic predisposition, environmental triggers, and dysregulated immune responses. The disease is characterized by a Th2 and regulatory T-cell (Treg) dominated immune response, with interleukin-4 (IL-4), IL-5, IL-10, IL-13, and transforming growth factor-β (TGF-β) playing crucial roles in disease pathogenesis.²

The characteristic tissue infiltration involves not only IgG4-positive plasma cells but also regulatory T cells, M2 macrophages, and eosinophils. This cellular milieu promotes fibrosis through TGF-β signaling while simultaneously creating an immunosuppressive microenvironment that may explain the disease's responsiveness to corticosteroids.³

Genetic Associations

Recent genome-wide association studies have identified several susceptibility loci, including HLA-DRB104:05 and HLA-DQB104:01 in Japanese populations, suggesting genetic predisposition plays a role in disease development.⁴ The discovery of complement factor H-related protein 1 (FHR1) deletions and variations in genes encoding cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) further supports the immunogenetic basis of IgG4-RD.

Teaching Point: Understanding the Th2/Treg-dominated pathophysiology explains why IgG4-RD responds so dramatically to corticosteroids—we're not just suppressing inflammation, we're interrupting the fundamental immune dysregulation driving the disease process.

Clinical Manifestations and Organ System Involvement

Pancreatic Involvement: Autoimmune Pancreatitis

Autoimmune pancreatitis (AIP) remains the most recognized manifestation of IgG4-RD, presenting in two distinct forms:

Type 1 AIP (IgG4-related):

Diffuse pancreatic enlargement with "sausage-like" appearance
Loss of pancreatic lobular architecture
Delayed enhancement on contrast imaging
Irregular narrowing of the main pancreatic duct
Elevated serum IgG4 in 60-70% of cases⁵

Type 2 AIP (Idiopathic duct-centric pancreatitis):

Focal pancreatic lesions
Granulocytic epithelial lesions on histology
Normal serum IgG4 levels
Often associated with inflammatory bowel disease

Critical Care Considerations: Patients may present with acute pancreatitis, biliary obstruction, or pancreatic masses suspicious for malignancy. The challenge lies in distinguishing AIP from pancreatic adenocarcinoma, particularly when focal lesions are present.

Diagnostic Hack: The "duct penetrating sign" on MRCP—where the pancreatic duct remains visible through areas of pancreatic enlargement—is highly suggestive of AIP and helps differentiate it from pancreatic cancer, where the duct is typically obstructed.

Retroperitoneal Manifestations

Retroperitoneal fibrosis (RPF) represents one of the most dramatic presentations of IgG4-RD, with potential for life-threatening complications:

Clinical Presentations:

Periaortic soft tissue thickening ("inflammatory aortic aneurysm")
Ureteral obstruction leading to hydronephrosis
Inferior vena cava compression
Renal failure secondary to ureteral obstruction⁶

Imaging Characteristics:

CT/MRI showing soft tissue masses encasing retroperitoneal structures
"Halo sign" around the aorta
Bilateral ureteral involvement (distinguishing from malignancy)

Emergency Management Pearls:

Urgent urological consultation for ureteral stenting if hydronephrosis present
Consider immediate corticosteroid therapy if IgG4-RD suspected
Monitor renal function closely during initial treatment

Orbital and Ocular Involvement

IgG4-related ophthalmic disease can present with diverse manifestations that may require urgent intervention:

Common Presentations:

Orbital pseudotumor with proptosis
Lacrimal gland enlargement
Extraocular muscle fibrosis
Dacryoadenitis and dry eye syndrome
Orbital apex syndrome with vision loss⁷

Critical Recognition Points:

Bilateral involvement (though may be asymmetric)
Painless or minimally painful (unlike typical orbital cellulitis)
Progressive visual field defects
Associated systemic symptoms

Oyster: While orbital IgG4-RD typically presents as a slowly progressive condition, acute presentations with rapid vision loss can occur due to compressive optic neuropathy. Early recognition and immediate corticosteroid therapy can prevent permanent visual impairment.

Pulmonary Manifestations

Pulmonary IgG4-RD presents with protean manifestations that frequently challenge differential diagnosis:

Imaging Patterns:

Multiple pulmonary nodules (mimicking metastases)
Ground-glass opacities
Consolidative lesions
Mediastinal lymphadenopathy
Pleural involvement with thickening or effusions⁸

Histopathological Variants:

Organizing pneumonia pattern
Nodular/mass-forming lesions
Interstitial pneumonia pattern
Pleuritis with pleural nodules

Critical Care Implications: Patients may present with respiratory failure, and the radiological appearance often raises immediate concern for malignancy or infection, leading to urgent interventions including bronchoscopy, CT-guided biopsy, or even thoracotomy.

Diagnostic Approach: The Systematic Method

Clinical Assessment Framework

The "HISSTER" Approach for IgG4-RD Recognition:

History of multiorgan involvement
Imaging showing characteristic patterns
Serum IgG4 elevation
Storiform fibrosis on histology
Tissue infiltration with IgG4+ plasma cells
Eosinophilia (often present)
Response to corticosteroids

Histopathological Gold Standard

The diagnosis of IgG4-RD rests on three cardinal histopathological features:

Dense lymphoplasmacytic infiltrate
Storiform fibrosis - the characteristic "cartwheel" or "spoke-wheel" pattern of collagen deposition
Obliterative phlebitis - inflammatory infiltration and narrowing of veins⁹

Quantitative Criteria:

40 IgG4+ plasma cells per high-power field (most organs)
10 IgG4+ plasma cells per high-power field (mucosa-rich organs)
IgG4+/IgG+ plasma cell ratio >40%

Biopsy Strategy Pearl: When planning biopsies, target the most accessible involved organ, but avoid necrotic or heavily fibrotic areas. The cellular infiltrate is typically most prominent at the periphery of lesions and in areas of active inflammation.

Serological Markers

Serum IgG4:

Elevated (>135 mg/dL) in approximately 60-70% of patients
Not pathognomonic—can be elevated in other conditions
Correlates with disease activity and treatment response
May normalize with successful therapy¹⁰

Additional Laboratory Findings:

Eosinophilia (30-40% of patients)
Elevated ESR and CRP during active disease
Complement consumption (C3, C4 depression)
Rheumatoid factor positivity (occasionally)
Low-level ANA positivity (non-specific pattern)

Laboratory Hack: Don't rely solely on serum IgG4 levels. A normal IgG4 doesn't exclude the disease, and an elevated level doesn't confirm it. Use IgG4 levels as supportive evidence within the broader clinical context.

Imaging Strategies

Multi-organ Assessment Protocol:

Contrast-enhanced CT chest/abdomen/pelvis - initial screening
MRI with MRCP - detailed pancreatic and biliary assessment
PET-CT - evaluation of disease extent and metabolic activity
Organ-specific imaging as indicated (orbital MRI, cardiac MRI, etc.)

Characteristic Imaging Findings:

Hypodense lesions on unenhanced CT
Delayed heterogeneous enhancement
T2-weighted hypointensity on MRI (fibrotic tissue)
Moderate FDG uptake on PET (distinguishing from malignancy)

Differential Diagnosis: The Mimicry Challenge

Malignancy Mimics

Pancreatic Adenocarcinoma vs. AIP:

Mass effect and duct obstruction favor malignancy
Smooth, tapering duct narrowing favors AIP
Capsule-like rim enhancement suggests AIP
Rapid progression suggests malignancy

Lymphoma vs. IgG4-RD:

Bulky lymphadenopathy more common in lymphoma
Extranodal involvement pattern differs
Flow cytometry and tissue architecture are diagnostic

Autoimmune Disease Mimics

Sjögren's Syndrome:

Salivary and lacrimal gland involvement overlap
Anti-Ro/La antibodies distinguish Sjögren's
Histological pattern of lymphoepithelial lesions differs

Inflammatory Bowel Disease:

Type 2 AIP association with IBD creates diagnostic confusion
Sclerosing cholangitis patterns overlap
Tissue IgG4 staining clarifies diagnosis

Infectious Disease Mimics

Fungal Infections:

Histoplasma, Blastomyces can cause similar pulmonary nodules
Tissue stains and cultures are diagnostic
Geographic distribution provides clues

Tuberculosis:

Granulomatous inflammation differs from IgG4-RD
Acid-fast staining and PCR testing distinguish

Clinical Decision Pearl: When encountering multiorgan disease with mass-forming lesions, always consider the "rule of 3s": 3 most common causes (malignancy, infection, autoimmune), 3 key diagnostic tests (biopsy, culture, specific markers), and 3 treatment approaches (targeted therapy, antimicrobials, immunosuppression).

Management Strategies

First-Line Therapy: Corticosteroids

Induction Protocol:

Prednisolone 0.6-1.0 mg/kg/day (maximum 40-60 mg daily)
Continue for 2-4 weeks depending on response
Begin tapering once clinical improvement evident
Total treatment duration: 6-12 months for most patients¹¹

Response Assessment:

Clinical improvement typically within 2-4 weeks
Imaging improvement may lag behind clinical response
Serum IgG4 levels decline with successful treatment
Organ function improvement (e.g., pancreatic exocrine function)

Tapering Strategy:

Reduce by 5-10 mg every 2 weeks initially
Slower tapering (2.5-5 mg reductions) below 20 mg daily
Monitor for disease flares during tapering
Consider alternate-day dosing for maintenance

Steroid-Sparing Agents

Indications for Second-Line Therapy:

Steroid-dependent disease
Contraindications to long-term corticosteroids
Relapsing disease
Severe disease at presentation

Evidence-Based Options:

Rituximab: 375 mg/m² weekly × 4 doses or 1000 mg × 2 doses
Azathioprine: 1.5-2.5 mg/kg daily
Methotrexate: 15-25 mg weekly
Mycophenolate mofetil: 1-2 g daily¹²

Emerging Therapies:

Iguratimod (T-cell and B-cell modulator)
Abatacept (CTLA-4 immunoglobulin)
Bortezomib (proteasome inhibitor)

Critical Care Management

Acute Presentations Requiring ICU Care:

Respiratory failure from pulmonary involvement
Acute renal failure from ureteral obstruction
Biliary sepsis from pancreatic head involvement
Cardiovascular compromise from mediastinal masses

Emergency Treatment Protocol:

Immediate Assessment: Airway, breathing, circulation
Urgent Interventions: As clinically indicated (intubation, drainage procedures)
Diagnostic Workup: Simultaneous with stabilization
Empirical Therapy: Consider high-dose corticosteroids if high suspicion
Multidisciplinary Consultation: Early involvement of relevant specialists

Monitoring Parameters:

Organ function markers (creatinine, liver enzymes, pancreatic enzymes)
Inflammatory markers (ESR, CRP)
Serum IgG4 levels
Imaging response assessment

Clinical Pearls and Practical Wisdom

Recognition Pearls

The "Red Flag" Combinations:

Middle-aged male + pancreatic mass + elevated IgG4 = Consider AIP
Bilateral orbital masses + retroperitoneal fibrosis = Think IgG4-RD
Multiple pulmonary nodules + pancreatic enlargement = IgG4-RD likely
Sclerosing cholangitis + normal inflammatory bowel disease workup = Consider IgG4-RD

Timing Pearls:

Disease typically affects middle-aged to elderly patients (peak: 50-70 years)
Male predominance in pancreatic disease (3:1)
Female predominance in orbital and salivary gland disease
Often insidious onset with months to years of symptoms

Diagnostic Pearls

Biopsy Timing:

Obtain tissue before starting corticosteroids when possible
If clinical urgency requires immediate steroids, biopsy within 48-72 hours
Steroid response itself can be diagnostic when tissue unavailable

Laboratory Interpretation:

Normal IgG4 levels don't exclude disease
Very high IgG4 levels (>5× normal) are more specific
Follow IgG4 levels as biomarker of treatment response
Eosinophilia often accompanies active disease

Treatment Pearls

Steroid Response Patterns:

Rapid clinical improvement (days to weeks) is characteristic
Lack of initial response should prompt reconsideration of diagnosis
Some fibrotic changes may be irreversible despite treatment
Early treatment prevents progression to fibrotic stage

Long-term Management:

30-50% of patients experience disease relapse
Relapse more common with rapid steroid tapering
Maintenance therapy may be necessary in relapse-prone patients
Regular monitoring for treatment-related complications

Oysters (Rare but Important Pearls)

The Aortic Aneurysm Oyster: Inflammatory abdominal aortic aneurysms associated with IgG4-RD can present with rupture. The combination of retroperitoneal fibrosis and aneurysmal disease creates a unique surgical challenge requiring coordinated vascular and urological approaches.

The Cardiac Oyster: IgG4-related cardiac disease can present as constrictive pericarditis, coronary artery involvement, or valvular disease. These presentations are rare but can be life-threatening and require immediate cardiac intervention alongside immunosuppressive therapy.¹³

The Neurological Oyster: Central nervous system involvement in IgG4-RD can present as pachymeningitis, hypophysitis, or orbital apex syndrome with rapid visual loss. These manifestations require emergency high-dose corticosteroids to prevent irreversible neurological damage.

Prognosis and Long-term Outcomes

Disease Course Patterns

Response Categories:

Complete responders (40-50%): Full resolution with treatment
Partial responders (30-40%): Significant improvement with residual disease
Non-responders (5-10%): Minimal improvement despite therapy
Relapsing disease (30-50%): Recurrence after initial response¹⁴

Prognostic Factors:

Favorable Indicators:

Early diagnosis and treatment
Predominantly inflammatory (vs. fibrotic) disease
Single-organ involvement
Good initial steroid response

Poor Prognostic Indicators:

Delayed diagnosis with extensive fibrosis
Multiorgan involvement (>3 organs)
Very high initial IgG4 levels (>5× normal)
Eosinophilia >1000/μL

Long-term Complications

Treatment-Related:

Corticosteroid toxicity (osteoporosis, diabetes, infections)
Immunosuppressive agent side effects
Increased infection risk

Disease-Related:

Irreversible organ damage from untreated fibrosis
Malignancy risk (controversial, requires further study)
Quality of life impact from chronic disease

Future Directions and Research Frontiers

Biomarker Development

Emerging Biomarkers:

Plasmablast levels in peripheral blood
Soluble IL-2 receptor levels
IgE/IgG4 ratios
Complement factor profiles

Potential Applications:

Earlier diagnosis
Treatment response monitoring
Relapse prediction
Prognosis assessment

Therapeutic Advances

Novel Targets:

B-cell depletion strategies beyond rituximab
T-cell modulators (abatacept, belatacept)
Complement inhibitors
Fibrosis-specific therapies

Precision Medicine Approaches:

Genetic profiling for treatment selection
Organ-specific treatment protocols
Biomarker-guided therapy duration

Diagnostic Innovation

Advanced Imaging:

PET-MRI fusion for comprehensive assessment
Molecular imaging with specific tracers
AI-assisted radiological diagnosis

Tissue-Based Diagnostics:

Digital pathology with automated IgG4 quantification
Molecular signatures from tissue RNA sequencing
Liquid biopsy approaches

Conclusions and Key Take-Home Messages

IgG4-related disease represents a paradigm shift in our understanding of systemic inflammatory conditions. For the critical care physician and postgraduate trainee, several key principles emerge:

Essential Recognition Patterns: The constellation of multiorgan involvement, mass-forming lesions, characteristic histopathology, and dramatic steroid responsiveness creates a diagnostic signature that, once recognized, becomes unmistakable.

Diagnostic Strategy: A systematic approach combining clinical assessment, appropriate imaging, tissue sampling, and serological evaluation provides the foundation for accurate diagnosis. The key lies not in any single test, but in recognizing the pattern across multiple diagnostic modalities.

Therapeutic Principles: Early recognition and prompt treatment with corticosteroids can prevent irreversible organ damage. However, the high rate of relapse necessitates careful monitoring and often requires steroid-sparing agents for long-term management.

Critical Care Considerations: While IgG4-RD typically follows an indolent course, acute presentations requiring intensive care management do occur. The intensivist must maintain awareness of this condition in the differential diagnosis of unexplained multiorgan inflammatory processes.

Future Perspectives: The field continues to evolve rapidly, with advances in biomarker development, therapeutic targets, and diagnostic approaches promising improved outcomes for patients with this complex condition.

As educators and clinicians, our role extends beyond simple diagnosis and treatment. We must cultivate a systematic approach to complex multisystem diseases, maintain high clinical suspicion for mimicker conditions, and appreciate the profound impact that early recognition and appropriate therapy can have on patient outcomes.

The great mimicker teaches us humility in clinical practice while rewarding careful observation, systematic thinking, and persistent inquiry. In the end, IgG4-RD exemplifies the art and science of modern medicine—where pattern recognition meets molecular understanding to transform patient care.

References

Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732-738.
Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol. 2010;34(12):1812-1819.
Shiokawa M, Kodama Y, Kuriyama K, et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut. 2016;65(8):1322-1332.
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21-30.
Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol. 2009;7(10):1097-1103.
Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688-1699.
Tiegs-Heiden CA, Eckel LJ, Hunt CH, et al. Immunoglobulin G4-related disease of the orbit: imaging features in 27 patients. AJNR Am J Neuroradiol. 2014;35(7):1393-1397.
Matsui S, Hebisawa A, Sakai F, et al. Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respirology. 2013;18(3):480-487.
Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-1192.
Wallace ZS, Deshpande V, Mattoo H, et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015;67(9):2466-2475.
Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460-1471.
Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171-1177.
Kasashima S, Zen Y, Kawashima A, et al. Inflammatory abdominal aortic aneurysm: close relationship to IgG4-related disease. Am J Surg Pathol. 2008;32(2):197-204.
Wallace ZS, Zhang Y, Perugino CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78(3):406-412.

Saturday, June 28, 2025